Pharmaceutical companies are adjusting to changes in U.S. policy for 2026 that include initiatives to lower drug prices and shift investments to the U.S.[2] Some companies plan to sell directly to patients in the U.S. and offer discounts of up to 80% on select drugs in partnership with government or state programs.The administration is preparing to launch TrumpRx.gov in early 2026 to make it easier to access reduced prescription drug prices.[2] Large pharmaceutical companies are increasing investment and expanding research centers in the U.S.; for example, AstraZeneca announced a plan to invest $50 billion in the U.S. over five years, and Novartis announced a five-year, $23 billion plan.[1][1] Pressure to shift investment to the US is a concern in Europe, with analyses suggesting that up to 85% of planned capital investment could be at risk, and a reduction in regulatory data protection periods may also interfere with decision-making.4 Changes in pricing policies, including threats of drug tariffs and regulatory reforms, are key factors shaping companies' strategies for 2026.3[4][5][6] The US is also a key market leader in the development of new drugs.